Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D

This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Intern Med
Glavni autori: DeJong, Colette, Masuda, Camlyn, Chen, Randi, Kazi, Dhruv S., Dudley, R. Adams, Tseng, Chien-Wen
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2020
Teme:
Research Letter
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7490744/
https://ncbi.nlm.nih.gov/pubmed/32926091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.2922
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items